Sign in

CIK 0001766140

  • Emerging growth company

Unicycive Therapeutics, Inc.

Sign in to watch
Ticker
UNCY
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
813638692
Phone
+1 650-384-0642
Business address
1975 W. EL CAMINO REAL, SUITE 204, MOUNTAIN VIEW, CA, 94040
Former names
Unicycive Therapeutics, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2025-08-25 Aggarwal Gaurav Director Conversion +652,900 1,789,915
2025-08-25 Aggarwal Gaurav Director Returned to the company · Series A-2 Prime Preferred Stock −3,199.21 $1,000.00 $3.2M 0
2025-07-28 Aggarwal Gaurav Director Grant or award · Stock Options +21,200 39,200
2025-02-18 Aggarwal Gaurav Director Conversion +1,400,000 11,370,152
2025-02-18 Aggarwal Gaurav Director Returned to the company · Series A-2 Prime Preferred Stock −686 $1,000.00 $686K 3,119.21
2024-10-09 Aggarwal Gaurav Director Conversion +5,500,000 9,970,152
2024-10-09 Aggarwal Gaurav Director Returned to the company · Series A-2 Prime Preferred Stock −2,695 $1,000.00 $2.7M 3,885.21
2023-09-05 Aggarwal Gaurav Director Grant or award · Stock Options +180,000 180,000
2023-07-11 Aggarwal Gaurav Director Conversion +3,470,152 3,470,152
2023-07-11 Aggarwal Gaurav Director Conversion · Series A-1 Preferred Stock −8,077 $1,000.00 $8.1M 0
2023-07-11 Aggarwal Gaurav Director Conversion · Series A-2 Preferred Stock +13,429,000 13,429,000
2023-07-11 Aggarwal Gaurav Director Conversion · Tranche A Warrants (right to buy) +12,802,388 12,802,388
2023-07-11 Aggarwal Gaurav Director Conversion · Tranche B Warrants (right to buy) +11,638,534 11,638,534
2023-07-11 Aggarwal Gaurav Director Conversion · Tranche C Warrants (right to buy) +18,621,655 18,621,655
2023-03-08 Aggarwal Gaurav Director Grant or award · Series A-1 Convertible Preferred Stock +8,077 $1,000.00 $8.1M 8,077

Page 1 of 1 · 15 trades